Paclitaxel–Anthracycline Combination Chemotherapy in Relapsing Advanced Ovarian Cancer after Platinum-Based Chemotherapy: A Pilot Study |
| |
Authors: | JE Kurtz MD G Deplanque MD B Duclos MD F Eichler MD C Giron MD JM Limacher MD R Herbrecht MD F Maloisel MD F Oberling MD JP Bergerat MD P Dufour MD |
| |
Institution: | Department of Onco-Hematology, Hôpitaux Universitaires, 67098, Strasbourg, France |
| |
Abstract: | Despite high response rates with platinum-based front-line chemotherapy, the prognosis for advanced ovarian carcinoma (AOC) is poor. Salvage chemotherapy for recurrent AOC was of little benefit before paclitaxel as single-agent therapy showed appreciable efficacy. Anthracyclines are effective, but are not often part of first-line therapy. In this pilot study, we investigated the feasibility of an anthracycline plus paclitaxel combination therapy for recurrent AOC. Twenty-four patients received 150 mg/m2paclitaxel on day 1, with either 50 mg/m2doxorubicin on day 1 or 75 mg/m2epirubicin on day 1 every 3 weeks. A 27% overall response rate was obtained. Myelosuppression was the major toxicity, but was manageable. No myocardiac toxicity was observed. We conclude that paclitaxel–anthracyclines is a promising salvage combination therapy in AOC that should be investigated further. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|